FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Hepatitis C virus (HCV) infection is highly associated with the development of metabolic dysfunction-associated steatotic ...

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...

The culprit is a virus called hepatitis C virus (HCV), which typically gets into a person’s system through direct contact with infected blood. Once inside the body, it hones in on liver cells ...

Six patients were found to have hepatitis C viremia ... The anesthesiology assistant contracted HCV from Patient 1 and subsequently transmitted the virus, during the incubation stage of his ...

Patients infected with Hepatitis C Virus (HCV) often present with rheumatic symptoms, but its link to rheumatoid arthritis ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

Discover 7 destructive ways hepatitis C attacks liver tissue. Learn how this viral infection progresses from inflammation to ...

The Hepatitis C Elimination Coalition commends Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) for their bipartisan ...

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

It is an immunoassay for the qualitative detection of immunoglobin G (IgG) antibodies to hepatitis C virus (anti-HCV) in oral fluid, fingerstick whole blood, venipuncture whole blood, plasma ...

The hepatitis C virus (HCV) testing market is forecasted to exhibit a 5.4% CAGR through 2033, as per FMI’s analysis. The industry’s size is predicted to extrapolate from USD 785.3 million in 2023 to ...